Jiangsu Vcare Launches Phase II Trial for VC005 Topical Gel in Mild-to-Moderate Atopic Dermatitis
Published Time:
2025-03-26 18:05
Source:
On March 26, 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) officially launched the Phase II clinical trial for its self-developed, highly selective JAK1 inhibitor VC005 gel for the topical treatment of mild-to-moderate atopic dermatitis (AD). The completed Phase I clinical study of VC005 gel demonstrated excellent safety and significant efficacy.
Currently, the oral tablet formulation of VC005 for moderate-to-severe AD has completed the first dosing of patients in Phase III clinical trials, with favorable safety results.
About VC005
VC005 is a novel, potent, and highly selective second-generation JAK1 inhibitor independently developed by Jiangsu Vcare. By selectively inhibiting JAK1, the drug reduces inflammatory responses and immune cell activation, making it clinically applicable for treating inflammatory and autoimmune diseases. Compared to the marketed leading drug Upadacitinib, VC005 exhibits lower JAK2 inhibitory activity (based on in vitro kinase assay results), potentially mitigating safety concerns associated with excessive JAK2 inhibition. The oral tablet formulation of VC005 is actively undergoing a Phase II clinical trial for ankylosing spondylitis and a Phase III trial for moderate-to-severe AD, which have yielded positive results. The topical gel formulation for mild-to-moderate AD has completed Phase I studies, demonstrating outstanding safety and efficacy.
About Atopic Dermatitis (AD)
Atopic dermatitis is a chronic, recurrent, inflammatory skin disease characterized by dry skin, intense itching, and eczematous rashes. The disease significantly impairs patients' quality of life. Epidemiologically, the global AD patient population is approximately 230 million, with an adult prevalence rate of 2%–8% in China, affecting over 70 million individuals. Among these, 67% are mild cases and 33% are moderate-to-severe. Frost & Sullivan predicts that the number of cases will grow at a compound annual growth rate (CAGR) of 1.7% from 2025 to 2030. Traditional treatments, such as glucocorticoids, are associated with numerous adverse reactions and limited long-term benefits, making disease control challenging. Meanwhile, topical JAK1 small-molecule targeted inhibitors, as non-glucocorticoid immunosuppressants, offer promising efficacy and safer choices for mild-to-moderate AD patients.
Related News
11
2026
/
06
Recently, VC005 topical gel, a new-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech), has officially obtained the IND approval from the CDE for the topical treatment of plaque psoriasis.
View Details
09
2026
/
06
9 June 2026 – Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech，Company), a commercial-stage innovative biopharmaceutical firm leveraging AI for differentiated original drug design, today announced the signing of an exclusive licensing agreement with Everest Medicines (HKEX: 1952.HK). Under the deal, Vcare PharmaTech grants Everest Medicines exclusive rights for the clinical development, registration and commercialization of Sumecigrel (formerly known as Vicagrel) across multiple Asia-Pacific countries and regions (including Southeast Asia, South Korea, Australia, Hong Kong SAR, Macao SAR and Taiwan region of China).
View Details
04
2026
/
06
On June 4, the official website of the NMPA announced that Vcare PharmaTech’s Class 1 new drug, Eratrectinib (VELMARTO®), has been approved for marketing in China. It is indicated for adult and adolescent patients with advanced solid tumors harboring NTRK gene fusions.
View Details
02
2026
/
06
Capital Empowers Innovation: Vcare PharmaTech Completes Nearly RMB 200 Million Series C3 Financing
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) has successfully closed its Series C3 financing totaling nearly RMB 200 million. The round was led by existing shareholder Hongcheng Investment, with follow-on investments from institutions including Xinghe Venture Capital, Hangzhou Jinlong, Hongyao Kechuang and Huadian Investment. Meanwhile, the firm has onboarded high-caliber new investors such as Huafuruixing, consolidating a solid capital foundation for its sustainable long-term growth.
View Details
12
2026
/
05
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Jiangsu Vcare) announced that VC005 Topical Gel, its self-developed second-generation highly selective JAK1 inhibitor, has completed the enrollment of the first patient in the phase III clinical trial for the treatment of mild-to-moderate atopic dermatitis (AD).
View Details
07
2026
/
05
Recently, VC005 Topical Gel, a second-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), has officially obtained the IND approval from the CDE of the NMPA. The product is intended for the topical treatment of non-segmental vitiligo.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
苏公网安备32011202001742号
Powerby：www.300.cn nanjing.300.cn